v3.26.1
Other Receivable, Net - Schedule of Other Receivable (Details) - USD ($)
Mar. 31, 2026
Dec. 31, 2025
Other Receivables Net    
Loan receivable [1] $ 9,020,630 $ 14,355,283
Proceeds receivable from sale of subsidiary [2] 2,454,280 2,416,086
Other 234,859 559
Other receivables, net $ 11,709,769 $ 16,771,928
[1]

During the year ended December 31, 2025, the Company entered into five borrowing arrangements with a third party for an aggregate principal amount of $14,383,955, bearing interest at 9% per annum. Certain borrowings were guaranteed by individuals or entities or secured by certain assets. As of March 31, 2026, the outstanding balance of these borrowings and the associated interests were $8,815,666 and $204,964, respectively.

 

To date, all of the above borrowings, including the related accrued interest, had been fully repaid.
[2] The amount represents the receivable from the sale of SYCI, which is due in December, 2026 from Shandong Rongyuan Pharmaceutical Co., Ltd.